Article ID Journal Published Year Pages File Type
6243147 European Journal of Radiology 2016 10 Pages PDF
Abstract
This study found a significant difference between Choi versus RECIST 1.1, mRECIST and EASL when evaluating the response to sorafenib in HCC patients.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Radiology and Imaging
Preview
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Authors
, , , , , , ,